رجوع
42
مُدرج أيضًا باسم
CLPBF
OTC
نطاق اليوم
KWD 6.53
KWD 6.72
نطاق 52 أسبوعًا
KWD 6.53
KWD 11.44
حجم التداول
96,729
متوسط 50 يوم / 200 يوم
KWD 7.87
/
KWD 8.90
الإغلاق السابق
KWD 6.59
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 4.3 | 0.4 |
| P/B | 0.9 | 2.9 |
| ROE % | 20.1 | 3.7 |
| Net Margin % | 13.1 | 3.8 |
| Rev Growth 5Y % | 7.8 | 10.0 |
| D/E | 1.4 | 0.2 |
النقاط الرئيسية
Revenue grew 7.82% annually over 5 years — modest growth
Earnings declined -32.21% over the past year
ROE of 20.09% indicates high profitability
Generating 5.03B in free cash flow
P/E of 4.33 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 10.69%
النمو
Revenue Growth (5Y)
7.82%
Revenue (1Y)-2.87%
Earnings (1Y)-32.21%
FCF Growth (3Y)29.80%
الجودة
Return on Equity
20.09%
ROIC13.79%
Net Margin13.05%
Op. Margin27.19%
الأمان
Debt / Equity
1.40
Current Ratio1.61
Interest Coverage9.19
التقييم
P/E Ratio
4.33
P/B Ratio0.92
EV/EBITDA5.12
Dividend Yield0.04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -2.87% | Revenue Growth (3Y) | 3.52% |
| Earnings Growth (1Y) | -32.21% | Earnings Growth (3Y) | -15.38% |
| Revenue Growth (5Y) | 7.82% | Earnings Growth (5Y) | -8.21% |
| Profitability | |||
| Revenue (TTM) | 26.25B | Net Income (TTM) | 3.43B |
| ROE | 20.09% | ROA | 7.07% |
| Gross Margin | 65.06% | Operating Margin | 27.19% |
| Net Margin | 13.05% | Free Cash Flow (TTM) | 5.03B |
| ROIC | 13.79% | FCF Growth (3Y) | 29.80% |
| Safety | |||
| Debt / Equity | 1.40 | Current Ratio | 1.61 |
| Interest Coverage | 9.19 | Dividend Yield | 0.04% |
| Valuation | |||
| P/E Ratio | 4.33 | P/B Ratio | 0.92 |
| P/S Ratio | 0.56 | PEG Ratio | -1.10 |
| EV/EBITDA | 5.12 | Dividend Yield | 0.04% |
| Market Cap | 14.82B | Enterprise Value | 36.55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 26.25B | 27.03B | 24.50B | 22.58B | 19.43B |
| Net Income | 3.43B | 5.05B | 4.78B | 4.71B | 4.83B |
| EPS (Diluted) | 1.52 | 2.25 | 2.22 | 2.21 | 2.26 |
| Gross Profit | 17.08B | 18.27B | 16.33B | 15.53B | 13.31B |
| Operating Income | 7.14B | 7.32B | 6.77B | 6.44B | 6.36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 48.46B | 48.07B | 48.16B | 34.96B | 15.84B |
| Total Liabilities | 32.31B | 30.13B | 30.86B | 26.66B | 7.67B |
| Shareholders' Equity | 16.15B | 17.94B | 17.30B | 8.29B | 8.17B |
| Total Debt | 22.68B | 22.63B | 19.57B | 18.71B | 2.79B |
| Cash & Equivalents | 948.88M | 788.00M | 911.00M | 414.00M | 448.00M |
| Current Assets | 10.47B | 10.44B | 9.94B | 8.77B | 6.99B |
| Current Liabilities | 6.52B | 10.20B | 16.31B | 7.34B | 6.31B |
درجات الاستراتيجيات
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#216 of 658
النشاط الأخير
دخل
Contrarian Investing (David Dreman)
Mar 24, 2026